Minims Pilocarpine Nitrate

Valsts: Jaunzēlande

Valoda: angļu

Klimata pārmaiņas: Medsafe (Medicines Safety Authority)

Aktīvā sastāvdaļa:

Pilocarpine nitrate 1%

Pieejams no:

Smith & Nephew Ltd

SNN (starptautisko nepatentēto nosaukumu):

Pilocarpine nitrate 1%

Deva:

4 %

Zāļu forma:

Eye drops, solution

Kompozīcija:

Active: Pilocarpine nitrate 1% Excipient: Purified water

Vienības iepakojumā:

Single use dropper, 20 x 0.5ml, 20 dose units

Klase:

Prescription

Receptes veids:

Prescription

Ražojis:

Merck KGaA

Produktu pārskats:

Package - Contents - Shelf Life: Single use dropper, 20 x 0.5ml - 20 dose units - 30 months from date of manufacture stored at 8° to 15°C (Cool) protect from light

Autorizācija datums:

1988-12-01

Produkta apraksts

NEW ZEALAND DATA SHEET
1 MINIMS (Pilocarpine Nitrate), eye drops solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 0.5 mL unit contains 10 mg Pilocarpine Nitrate.
3 PHARMACEUTICAL FORM
Clear, colourless, sterile, single-use eye drops.
4 CLINICAL PARTICULARS
4.1
Therapeutic Indications
Pilocarpine is used as a miotic, for reversing the action of weaker
mydriatics and in
the
emergency treatment of glaucoma.
4.2
Dose and Method of Administration
Adults (including the elderly) and children:
Instil dropwise into the eye according to the recommended dosage.
To induce miosis, one or
two drops should be used.
In cases of emergency treatment of acute narrow-angle glaucoma, one
drop should
be used
every five minutes until miosis is achieved.
4.3
Contraindications
Conditions where pupillary constriction is undesirable e.g. acute
iritis, pupillary block
glaucoma, acute uveitis, anterior uveitis, iridocyclitis, acute iritis
and some forms of
secondary glaucoma.
Hypersensitivity to any component of the preparation.
Patients with soft contact lenses should not use this preparation.
4.4
Special Warnings and Precautions for Use
Systemic reactions rarely occur when treating chronic simple glaucoma
at normal
doses.
However, in the treatment of acute closed-angle glaucoma the
possibility of
systemic reactions
must be considered because of the higher doses given. Caution is
particularly advised in
patients with acute heart failure, bronchial asthma, peptic
ulceration, hypertension, urinary
tract obstruction, Parkinson’s disease and corneal abrasions.
Retinal detachments have been caused in susceptible individuals and
those with pre-existing
retinal disease, therefore, fundus examination is advised in all
patients prior
to the initiation
of therapy.
Patients
with
chronic
glaucoma
on
long-term
pilocarpine
therapy
should
have
regular
monitoring of intraocular pressure and visual fields.
NEW ZEALAND DATA SHEET
Systemic absorption may be reduced by compressing the lacrimal sac at
the medial
canthus
for a minute during and followi